Regen BioPharma, Inc. Updates Shareholders on Status of Non-Dilutive Funding Opportunities

SAN DIEGO, California, August 25, 2016 /PRNewswire/ --

Regen BioPharma, Inc. (OTCQB: RGBP), (OTCQB: RGBPP), is pleased to announce that significant interest is being expressed by potential strategic partners with regards to the Company's proprietary assets. Previously, the Company had announced that partnering strategies were to be explored with the goal to provide sources of non-dilutive funding. Objective Capital Partners, LLC is serving as exclusive advisor to the Company and assisting in exploring strategic partnerships, co-development and licensing agreements to enhance shareholder value and provide sources of non-dilutive funding.  

     (Logo: http://photos.prnewswire.com/prnh/20160229/338345 )

"We are pleased with the progress being made by our advisor to identify potential partnerships that can support the growth needs of our several therapeutic assets including HemaXellerate, our most advanced asset for aplastic anemia and chemotherapy-induced myelosuppression, and our novel NR2F6 programs for immune oncology and autoimmune disorders," said David Koos, Ph.D., Regen's Chief Executive Officer.  "Over the past year, there have been numerous partnering transactions that have occurred between large pharmaceutical companies and smaller biotechnology companies like Regen which demonstrate an appetite for investment in early stage companies with novel technologies which address significant markets. While we cannot guarantee success in signing a licensing arrangement, we believe our assets will be able to attract the sort of best in class partners which will maximize the Company's success and that strategic partnerships will play a major role in the further development of our assets."  

Regen BioPharma's pipeline includes autologous cell therapies (HemaXellerate, dCellVax, tCellVax), universal donor cell therapy (ucVax) and small molecules (NR2F6 program). HemaXellerate is the subject of an Investigational New Drug Application (IND) and planned Phase I/II clinical trial that is intended to determine safety and potential efficacy of intravenously administered autologous stromal vascular fraction (SVF) cells in patients with severe, immune suppressive refractory aplastic anemia. The Company also intends to file an IND and pursue a Phase I/II clinical trial assessing HemaXellerate in patients suffering from chemotherapy-induced bone marrow suppression. Significant progress has been achieved with regards to Regen's NR2F6 Programs (a novel molecular switch or control center that modulates the immune system for which no known molecules that bind to it exist) in securing the intellectual property and  conducting preclinical testing with the goal of entering the market with an oral drug following further development.  

About Regen BioPharma Inc.: 

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP and (OTCQB: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on gene silencing therapy and small molecule therapies for treating cancer, along with developing stem cell treatments for aplastic anemia and disorders of the bone marrow. Additional information on Regen Biopharma is available at http://www.regenbiopharmainc.com.

About Objective Capital Partners, LLC: 

Objective Capital Partners is a leading M&A investment banking firm whose Principals have collectively engaged in more than 500 successful transactions serving the transaction needs of growth stage and mid-size companies. The executive team has a unique combination of investment banking, private equity, and business ownership experience that enables Objective Capital Partners to provide large enterprise caliber investment banking services to companies with annual revenues up to $500 million. Services include sale transactions, equity and debt capital raises and comprehensive advisory services. The firm uses a proprietary process to work to achieve premium company valuation, strong pricing, and high client satisfaction rates post-sale. The firm's industry expertise includes: life sciences, business services, software and hardware technology, aerospace/defense, IT services, healthcare services, energy services, biotech, consumer products and specialized manufacturing. Securities and investment banking services are offered through BA Securities, LLC Member FINRA, SIPC. The Principals of Objective Capital Partners are Registered Representatives of BA Securities. Objective Capital Partners and BA Securities are separate and unaffiliated entities. Additional information on Objective Capital Partners is available at http://www.objectivecp.com.

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

CONTACT INFORMATION

Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
http://www.regenbiopharma.com
[email protected]

Objective Capital Partner inquiries:
David H. Crean, Ph.D.
Managing Director
+1-858-461-9490
[email protected]

SOURCE Regen BioPharma Inc.